Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

Abstract

The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-gene signature that measures a pre-existing but suppressed adaptive immune response within tumors. The TIS has been shown to enrich for patients who respond to the anti-PD1 agent pembrolizumab. To explore this immune phenotype within and across tumor types, we applied the TIS algorithm to over 9000 tumor gene expression profiles downloaded from The Cancer Genome Atlas (TCGA). As expected based on prior evidence, tumors with known clinical sensitivity to anti-programmed cell death protein 1 (PD-1) blockade had higher average TIS scores. Furthermore, TIS scores were more variable within than between tumor types, and within each tumor type a subset of patients with elevated scores was identifiable although with different prevalence associated with each tumor type, the latter consistent with the observed clinical responsiveness to anti PD-1 blockade. Notably, TIS scores only minimally correlated with mutation load in most tumors and ranking tumors by median TIS score showed differing association to clinical sensitivity to PD-1/PD-1 ligand 1 (PD-L1) blockade than ranking of the same tumors by mutation load. The expression patterns of the TIS algorithm genes were conserved across tumor types yet appeared to be minimally prognostic in most cancers, consistent with the TIS score serving as a pan-cancer measurement of the inflamed tumor phenotype. Characterization of the prevalence and variability of TIS will lead to increased understanding of the immune status of untreated tumors and may lead to improved indication selection for testing immunotherapy agents.Electronic supplementary materialThe online version of this article (10.1186/s40425-018-0367-1) contains supplementary material, which is available to authorized users.

Immune checkpoint inhibitors: The linchpins of modern immunotherapy

“…The cancer Immunogram incorporates multiple microenvironmental signatures, including general immune status through lymphocyte count, soluble inhibitors such as interleukin 6 and C‐reactive protein, as well as genetic complexity, immune cell infiltration, and expression of checkpoint proteins . Multiparameter genetic expression signatures, such as Immunoscore, Tumor Inflammation Signature, and tumor immune dysfunction and exclusion (TIDE) scores offer an efficient snapshot of tumor cell, immune cell, and stromal contribution into anti‐tumor immunity, but have not been well‐explored in all cancers.…”

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

“…Figure 5C) and macrophages (Spearman correlation 0.71, p < 0.01) as estimated by xCell 34 . Established signatures describing the inflammatory TME and possible response to anti-PD1 therapy (tumor inflammatory score 35 , interferon gamma 36 , T-cell exhaustion 37 , and T-cell effector 38…”

Persistent cell proliferation signals correlates with increased glycolysis in tumor hypoxia microenvironment across cancer types

“…To calculate single-sample gene set enrichment, we used the GSVA program to derive the absolute enrichment scores of gene sets from several publications and previously experimentally validated gene signatures from MsigDB(https://www.gsea-msigdb.org/gsea/msigdb/) as follows: tumor proliferation signature [28] , tumor inflammation signature [62] , cellular response to hypoxia, MYC targets, DNA replication, G2M checkpoint, P53 pathway, PI3K/AKT/mTOR pathway, IFNG signaling, genes up-regulated by ROS, DNA repair, degradation of ECM, collagen formation, angiogenesis, EMT markers, apoptosis, TGFB signaling, and metabolism related pathways.…”